Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CT Vision S.L. (International) Holdings Limited 中天順聯 (國際) 控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 994)

RESIGNATION OF CHIEF EXECUTIVE OFFICER, REDESIGNATION OF DIRECTOR AND CHANGE OF AUTHORISED REPRESENTATIVE

RESIGNATION OF THE CHIEF EXECUTIVE OFFICER AND AUTHORISED REPRESENTATIVE AND REDESIGNATION TO NON-EXECUTIVE DIRECTOR

The board (the "Board") of directors (the "Directors") of CT Vision S.L. (International) Holdings Limited (the "Company", together with its subsidiaries, the "Group") hereby announces that Dr. Ho Chun Kit Gregory ("Dr. Ho") has tendered his resignation as the chief executive officer and the authorised representative of the Company ("Authorised Representative") under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and has been redesignated from executive Director to non-executive Director with effect from 25 April 2023 due to his health condition. After the redesignation, Dr. Ho will not take part in the daily operation of the Group but will provide advice on the strategic planning of the Group.

Dr. Ho has confirmed to the Board that he has no disagreement with the Board and there is nothing relating to his resignation as the chief executive officer and redesignation to a non-executive Director that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange of Hong Kong Limited (the "Stock Exchange").

The biographical details of Dr. Ho is set out below:

Dr. Ho, aged 45, has been redesignated from an executive Director to a non-executive Director with effect from 25 April 2023. Dr. Ho has also resigned as the chief executive officer of the Company. He joined the Group as an executive Director and the chief executive officer on 26 April 2019. He is also a director of certain subsidiaries of the Company.

Dr. Ho obtained his bachelor degree of Business Accounting from the Monash University of Australia in 2002 and completed his dissertation of "One Belt, One Road Post-Doctoral Research Programme" at the University of Oxford in May 2018. Dr. Ho has extensive experience in finance and investment, especially in the renewable energy and technology, media and telecom (TMT) industry. He has previously participated in the investment in smart energy cities in the People's Republic of China, which involved green building construction projects and application of renewable energy in the construction sector. Dr. Ho is currently the chairman of Asia-Pacific Smarter Energy Alliance (亞太智慧能源產業聯盟). Dr. Ho was an executive director of Century Energy International Holdings Limited (formerly known as China Oil Gangran Energy Group Holdings Limited), a company listed on GEM of the Stock Exchange (stock code: 08132) from May 2013 to February 2019. He was also an independent non-executive director of Asia Resources Holdings Limited, a company listed on the Main Board of the Stock Exchange (stock code: 00899) from February 2015 to October 2016, and an independent non-executive director of Koala Financial Group Limited (formerly known as Sunrise (China) Technology Group Limited), a company listed on GEM of the Stock Exchange (stock code: 08226) from April 2014 to August 2016.

Dr. Ho has entered into a service contract with the Company for a period of three years from 25 April 2023, subject to retirement by rotation and re-election in accordance with the articles of association of the Company. Pursuant to the service contract, Dr. Ho is receiving a director's fee and remuneration of HK\$600,000 per annum for his directorship in the Company, which was determined by reference to his background, qualifications, experience, duties and responsibilities with the Company as well as the prevailing market conditions.

Save as disclosed above, to the best of the knowledge, information and belief of the directors after having made all reasonable enquiries:

- (i) Dr. Ho does not hold any other positions in the Company or its subsidiaries nor directorship in other listed public company in Hong Kong or overseas in the last three years;
- (ii) Dr. Ho does not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company;
- (iii) Dr. Ho does not have and is not deemed to have any interests or short positions in shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and
- (iv) there was no other matter relating to his resignation as the chief executive officer and redesignation as non-executive Director that needs to be brought to the attention of the shareholders and there is no information that is required to be disclosed pursuant to Rule 13.51(2) (h) to (v) of the Listing Rules.

APPOINTMENT OF AUTHORISED REPRESENTATIVE

The Board further announces that Mr. Sun Dexin, the executive Director, has been appointed as the Authorised Representative with effect from 25 April 2023.

By Order of the Board
CT Vision S.L. (International) Holdings Limited
Sun Dexin

Executive Director

Hong Kong, 25 April 2023

As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Wu Rui, Mr. Guo Jianfeng and Mr. Sun Dexin, three non-executive Directors, namely Ms. Du Yi, Mr. Lu Qiwei and Dr. Ho Chun Kit Gregory, and three independent non-executive Directors, namely Dr. Tang Dajie, Mr. Ng Kwun Wan and Dr. Lin Tat Pang.